Drug GMP Warning Letter Downtrend Accelerates in FY 2003
This article was originally published in The Pink Sheet Daily
The number of FDA GMP warning letters fell to 29 in fiscal 2003 from 58 the previous year. Factors that may be at work include the agency’s new centralized clearance process and the diversion of FDA attention to other high-risk enforcement concerns.
You may also be interested in...
Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.
NDA and ANDA pilot programs will help transform the way CMC information is submitted and reviewed by FDA. Office of Generic Drugs' white paper on "question-based review" follows the introduction of an NDA pilot program in mid-July.
“Design Space” is emerging as a pivotal concept in FDA’s effort to integrate its pharmaceutical application review and inspection operations into a new “quality assessment” system. With regulatory flexibility for manufacturing changes in the balance, the agency will be working with industry to refine the concept and its application in drug development and manufacturing.